Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy study of elexacaftor + tezacaftor + ivacaftor in cystic fibrosis patients aged 6 years and older with F508del/minimal function genotype
MOH_2021-01-31_009709Phase 3Active, not recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of elexacaftor, tezacaftor and ivacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Started Jan 2021; status: active, not recruiting.
02
Drugs
elexacaftortezacaftorivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on MOH_2021-01-31_009709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-01-31_009709.